Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting
-
Published:2021-08
Issue:4
Volume:21
Page:317-328.e7
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Vidal Gregory A.,
Carter Gebra CuyunORCID,
Gilligan Adrienne M.,
Saverno Kim,
Zhu Yajun Emily,
Price Gregory L.,
DeLuca Angelo,
Smyth Emily Nash,
Rybowski Sarah,
Huang Yu-Jing,
Schwartzberg Lee S.
Funder
Eli Lilly and Company
Subject
Cancer Research,Oncology
Reference52 articles.
1. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review;Caswell-Jin;JNCI Cancer Spectr,2018
2. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4);Cardoso;Ann Oncol,2018
3. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer;D’Souza;J Hematol Oncol,2018
4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
5. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease;Dickler;J Clin Oncol,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献